August 4, 2016
(STAT News) – GlaxoSmithKline has developed what looks like a cure for a rare and deadly disease, and it’s going to cost $665,000 for a single dose. That sky-high price tag — more than twice the average price of a house — is likely to stir what’s already a long-simmering debate in health care: How much should curative therapies cost, and how should society pay for them? GSK’s drug, called Strimvelis, is a gene therapy for severe combined immune deficiency, an inborn illness that leaves children unable to protect themselves against infection.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.